Board of Scientific Counselors, Office of Infectious Diseases (BSC, OID), 67651 [2012-27541]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 219 / Tuesday, November 13, 2012 / Notices
srobinson on DSK4SPTVN1PROD with
Non-labor/capital costs: $6,111,000.
Request for Comment: You can file a
comment online or on paper. For the
Commission to consider your comment,
we must receive it on or before
December 13, 2012. Write ‘‘Subpart N of
Regulation V, PRA Comment, P125403’’
on your comment. Your comment—
including your name and your state—
will be placed on the public record of
this proceeding, including to the extent
practicable, on the public Commission
Web site, at https://www.ftc.gov/os/
publiccomments.shtm. As a matter of
discretion, the Commission tries to
remove individuals’ home contact
information from comments before
placing them on the Commission Web
site.
Because your comment will be made
public, you are solely responsible for
making sure that your comment does
not include any sensitive personal
information, like anyone’s Social
Security number, date of birth, driver’s
license number or other state
identification number or foreign country
equivalent, passport number, financial
account number, or credit or debit card
number. You are also solely responsible
for making sure that your comment does
not include any sensitive health
information, like medical records or
other individually identifiable health
information. In addition, do not include
any ‘‘[t]rade secret or any commercial or
financial information which is * * *
privileged or confidential’’ as provided
in Section 6(f) of the FTC Act 15 U.S.C.
46(f), and FTC Rule 4.10(a)(2), 16CFR
4.10(a)(2). In particular, do not include
competitively sensitive information
such as costs, sales statistics,
inventories, formulas, patterns, devices,
manufacturing processes, or customer
names.
If you want the Commission to give
your comment confidential treatment,
you must file it in paper form, with a
request for confidential treatment, and
you have to follow the procedure
explained in FTC Rule 4.9(c).5 Your
comment will be kept confidential only
if the FTC General Counsel, in his or her
sole discretion, grants your request in
accordance with the law and the public
interest.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online. To make sure that the
Commission considers your online
5 In
particular, the written request for confidential
treatment that accompanies the comment must
include the factual and legal basis for the request,
and must identify the specific portions of the
comment to be withheld from the public record. See
FTC Rule 4.9(c), 16 CFR 4.9(c).
VerDate Mar<15>2010
17:08 Nov 09, 2012
Jkt 229001
comment, you must file it at https://
ftcpublic.commentworks.com/ftc/
SubpartNRegulationVPRA2, by
following the instructions on the webbased form. If this Notice appears at
https://www.regulations.gov/#!home, you
also may file a comment through that
Web site.
If you file your comment on paper,
write ‘‘Subpart N of Regulation V, PRA
Comment, P125403’’ on your comment
and on the envelope, and mail or deliver
it to the following address: Federal
Trade Commission, Office of the
Secretary, Room H–113 (Annex J), 600
Pennsylvania Avenue NW., Washington,
DC 20580. If possible, submit your
paper comment to the Commission by
courier or overnight service.
Visit the Commission Web site at
www.ftc.gov to read this Notice. The
FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before December 13, 2012. You can find
more information, including routine
uses permitted by the Privacy Act, in
the Commission’s privacy policy, at
https://www.ftc.gov/ftc/privacy.htm.
Comments on the information
collection requirements subject to
review under the PRA should
additionally be submitted to OMB. If
sent by U.S. mail, they should be
addressed to Office of Information and
Regulatory Affairs, Office of
Management and Budget, Attention:
Desk Officer for the Federal Trade
Commission, New Executive Office
Building, Docket Library, Room 10102,
725 17th Street NW., Washington, DC
20503. Comments sent to OMB by U.S.
postal mail, however, are subject to
delays due to heightened security
precautions. Thus, comments instead
should be sent by facsimile to (202)
395–5167.
David C. Shonka,
Acting General Counsel.
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Office
of Infectious Diseases (BSC, OID)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
Frm 00025
Fmt 4703
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 8:00 a.m.–2:45 p.m.,
December 5, 2012.
Place: CDC, Global Communications
Center, 1600 Clifton Road NE., Building 19,
Auditorium B3, Atlanta, Georgia 30333.
Status: The meeting is open to the public,
limited only by the space available.
Purpose: The BSC, OID, provides advice
and guidance to the Secretary, Department of
Health and Human Services; the Director,
CDC; the Director, OID; and the Directors of
the National Center for Immunization and
Respiratory Diseases, the National Center for
Emerging and Zoonotic Infectious Diseases,
and the National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention, CDC, in
the following areas: strategies, goals, and
priorities for programs; research within the
national centers; and overall strategic
direction and focus of OID and the national
centers.
Matters To Be Discussed: The meeting will
include reports from the BSC OID working
groups, brief updates on activities of the
infectious disease national centers, and a
discussion on ways to strengthen the clinical
and public health interface, with focus on
addressing pertussis and implementing new
recommendations for reducing hepatitis C
virus morbidity and mortality.
Agenda items are subject to change as
priorities dictate.
CONTACT PERSON FOR MORE INFORMATION:
Robin Moseley, M.A.T., Designated Federal
Officer, OID, CDC, 1600 Clifton Road NE.,
Mailstop D10, Atlanta, Georgia 30333,
Telephone: (404) 639–4461.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: November 5, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–27541 Filed 11–9–12; 8:45 am]
BILLING CODE 4163–18–P
[FR Doc. 2012–27552 Filed 11–9–12; 8:45 am]
PO 00000
67651
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Title: Permanency Innovations
Initiative Evaluation: Phase 2.
OMB No.: 0970–0408.
Description: The Administration for
Children and Families (ACF), U.S.
Department of Health and Human
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67651]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27541]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, Office of Infectious Diseases
(BSC, OID)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Time and Date: 8:00 a.m.-2:45 p.m., December 5, 2012.
Place: CDC, Global Communications Center, 1600 Clifton Road NE.,
Building 19, Auditorium B3, Atlanta, Georgia 30333.
Status: The meeting is open to the public, limited only by the
space available.
Purpose: The BSC, OID, provides advice and guidance to the
Secretary, Department of Health and Human Services; the Director,
CDC; the Director, OID; and the Directors of the National Center for
Immunization and Respiratory Diseases, the National Center for
Emerging and Zoonotic Infectious Diseases, and the National Center
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the
following areas: strategies, goals, and priorities for programs;
research within the national centers; and overall strategic
direction and focus of OID and the national centers.
Matters To Be Discussed: The meeting will include reports from
the BSC OID working groups, brief updates on activities of the
infectious disease national centers, and a discussion on ways to
strengthen the clinical and public health interface, with focus on
addressing pertussis and implementing new recommendations for
reducing hepatitis C virus morbidity and mortality.
Agenda items are subject to change as priorities dictate.
CONTACT PERSON FOR MORE INFORMATION:
Robin Moseley, M.A.T., Designated Federal Officer, OID, CDC,
1600 Clifton Road NE., Mailstop D10, Atlanta, Georgia 30333,
Telephone: (404) 639-4461.
The Director, Management Analysis and Services Office has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Dated: November 5, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2012-27541 Filed 11-9-12; 8:45 am]
BILLING CODE 4163-18-P
